Here we show that DMF treatment influences Treg resistance, a key pathologic mechanism in MS patients, by normalizing elevated IL-6R expression and thus restoring susceptibility of T effector cells to Treg-mediated suppression. This evidence concerns the gene IL6R and myeloid sarcoma.